AR068369A1 - Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina" - Google Patents
Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"Info
- Publication number
- AR068369A1 AR068369A1 ARP080103848A ARP080103848A AR068369A1 AR 068369 A1 AR068369 A1 AR 068369A1 AR P080103848 A ARP080103848 A AR P080103848A AR P080103848 A ARP080103848 A AR P080103848A AR 068369 A1 AR068369 A1 AR 068369A1
- Authority
- AR
- Argentina
- Prior art keywords
- methylaminocarbonylmethylene
- pyrimidindiamine
- fenyl
- difluor
- oxazin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
El compuesto de la presente solicitud es una sustancia farmacéutica adecuada y util como inhibidor de S y K quinasa, También reivindica composicion farmacéutica, uso combinacion y proceso para prepararlo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97003007P | 2007-09-05 | 2007-09-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR068369A1 true AR068369A1 (es) | 2009-11-11 |
Family
ID=40293576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080103848A AR068369A1 (es) | 2007-09-05 | 2008-09-04 | Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina" |
Country Status (18)
Country | Link |
---|---|
US (3) | US8193181B2 (es) |
EP (1) | EP2215087B1 (es) |
JP (1) | JP2009084270A (es) |
KR (2) | KR20120120453A (es) |
CN (1) | CN101861314B (es) |
AR (1) | AR068369A1 (es) |
AU (1) | AU2008294473B2 (es) |
BR (1) | BRPI0816278A2 (es) |
CA (1) | CA2697495C (es) |
ES (1) | ES2452965T3 (es) |
HK (1) | HK1144685A1 (es) |
IL (1) | IL203973A (es) |
MX (1) | MX2010002518A (es) |
NZ (1) | NZ583582A (es) |
RU (1) | RU2458925C2 (es) |
TW (1) | TWI371277B (es) |
WO (1) | WO2009031011A2 (es) |
ZA (1) | ZA201002356B (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0908772D0 (en) * | 2009-05-21 | 2009-07-01 | Astrazeneca Ab | New salts 756 |
UY32648A (es) | 2009-05-21 | 2010-12-31 | Astrazeneca Ab | Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades |
US9145391B2 (en) | 2011-05-10 | 2015-09-29 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as Syk inhibitors |
RU2013154412A (ru) | 2011-05-10 | 2015-06-20 | Мерк Шарп И Доум Корп. | Аминопиримидины в качестве ингибиторов syc |
AU2012253886A1 (en) | 2011-05-10 | 2013-10-31 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as Syk inhibitors |
EP2763975B1 (en) | 2011-10-05 | 2016-04-06 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
WO2013052394A1 (en) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
WO2013052391A1 (en) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
US20130102596A1 (en) * | 2011-10-21 | 2013-04-25 | Rigel Pharmaceuticals, Inc. | Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo [1,4]oxazin-3-one)-6-yl]-5-fluoro-n2-[3- (methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine |
US9487504B2 (en) | 2012-06-20 | 2016-11-08 | Merck Sharp & Dohme Corp. | Imidazolyl analogs as syk inhibitors |
US9242984B2 (en) | 2012-06-20 | 2016-01-26 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as Syk inhibitors |
WO2013192098A1 (en) | 2012-06-22 | 2013-12-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
EP2863915B1 (en) | 2012-06-22 | 2017-12-06 | Merck Sharp & Dohme Corp. | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
US9353066B2 (en) | 2012-08-20 | 2016-05-31 | Merck Sharp & Dohme Corp. | Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors |
WO2014048065A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
US9624210B2 (en) | 2012-12-12 | 2017-04-18 | Merck Sharp & Dohme Corp. | Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors |
US9598405B2 (en) | 2012-12-21 | 2017-03-21 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors |
CA2902547A1 (en) * | 2013-03-14 | 2014-09-25 | Allergan, Inc. | Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process |
EP2988744A4 (en) | 2013-04-26 | 2016-11-02 | Merck Sharp & Dohme | THIAZOLE SUBSTITUTED AMINOHETEROARYL COMPOUNDS TYLOSINE KINASE SPLENIC INHIBITORS |
WO2014176216A1 (en) | 2013-04-26 | 2014-10-30 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors |
US9670196B2 (en) | 2013-12-20 | 2017-06-06 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors |
WO2015094997A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
US9822107B2 (en) | 2013-12-20 | 2017-11-21 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
WO2015138273A1 (en) | 2014-03-13 | 2015-09-17 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
WO2018189566A1 (en) * | 2017-04-10 | 2018-10-18 | Dorian Bevec | Use of a chemical compound as a therapeutic agent |
MX2021000611A (es) | 2018-07-18 | 2021-04-13 | Astrazeneca Ab | Una sal de xinafoato de un compuesto inhibidor de jak. |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
GB9808802D0 (en) * | 1998-04-24 | 1998-06-24 | Glaxo Group Ltd | Pharmaceutical formulations |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
GB0208609D0 (en) * | 2002-04-13 | 2002-05-22 | Glaxo Group Ltd | Compositions |
MXPA05003513A (es) * | 2002-10-04 | 2005-06-03 | Pharmacia Corp | Composiciones farmaceuticas para tratamiento de enfermedad de parkinson. |
CA2533377C (en) * | 2003-07-30 | 2012-11-27 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
NZ583872A (en) * | 2005-06-15 | 2011-10-28 | Boehringer Ingelheim Int | Process for preparing tiotropium salts, tiotropium salts as such and pharmaceutical compositions thereof |
SI2044025T1 (sl) * | 2006-06-30 | 2013-01-31 | Novartis Ag | Kinolinonski derivati in njihovi farmacevtski sestavki |
-
2008
- 2008-08-27 ES ES08806983.6T patent/ES2452965T3/es active Active
- 2008-08-27 EP EP08806983.6A patent/EP2215087B1/en not_active Not-in-force
- 2008-08-27 CN CN200880105757XA patent/CN101861314B/zh not_active Expired - Fee Related
- 2008-08-27 CA CA2697495A patent/CA2697495C/en not_active Expired - Fee Related
- 2008-08-27 KR KR1020127024371A patent/KR20120120453A/ko not_active Application Discontinuation
- 2008-08-27 MX MX2010002518A patent/MX2010002518A/es active IP Right Grant
- 2008-08-27 KR KR1020107007283A patent/KR101225233B1/ko active IP Right Grant
- 2008-08-27 RU RU2010108162/04A patent/RU2458925C2/ru active
- 2008-08-27 BR BRPI0816278A patent/BRPI0816278A2/pt not_active Application Discontinuation
- 2008-08-27 NZ NZ583582A patent/NZ583582A/en not_active IP Right Cessation
- 2008-08-27 AU AU2008294473A patent/AU2008294473B2/en not_active Ceased
- 2008-08-27 WO PCT/IB2008/002288 patent/WO2009031011A2/en active Application Filing
- 2008-08-27 US US12/676,075 patent/US8193181B2/en active Active
- 2008-09-03 JP JP2008225403A patent/JP2009084270A/ja active Pending
- 2008-09-04 TW TW097133970A patent/TWI371277B/zh not_active IP Right Cessation
- 2008-09-04 AR ARP080103848A patent/AR068369A1/es unknown
-
2010
- 2010-02-15 IL IL203973A patent/IL203973A/en active IP Right Grant
- 2010-04-01 ZA ZA2010/02356A patent/ZA201002356B/en unknown
- 2010-11-30 HK HK10111120.8A patent/HK1144685A1/xx not_active IP Right Cessation
-
2012
- 2012-05-09 US US13/467,850 patent/US8486935B2/en active Active
-
2013
- 2013-06-18 US US13/920,434 patent/US20130281446A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2008294473B2 (en) | 2013-12-05 |
US20120316160A1 (en) | 2012-12-13 |
CA2697495A1 (en) | 2009-03-12 |
CN101861314A (zh) | 2010-10-13 |
TW200927125A (en) | 2009-07-01 |
US8486935B2 (en) | 2013-07-16 |
IL203973A (en) | 2013-10-31 |
BRPI0816278A2 (pt) | 2015-09-22 |
KR20100049688A (ko) | 2010-05-12 |
CN101861314B (zh) | 2013-07-24 |
EP2215087B1 (en) | 2013-12-18 |
MX2010002518A (es) | 2010-03-26 |
JP2009084270A (ja) | 2009-04-23 |
CA2697495C (en) | 2013-02-05 |
RU2458925C2 (ru) | 2012-08-20 |
US20100204232A1 (en) | 2010-08-12 |
WO2009031011A3 (en) | 2009-04-30 |
HK1144685A1 (es) | 2011-03-04 |
NZ583582A (en) | 2012-02-24 |
US8193181B2 (en) | 2012-06-05 |
US20130281446A1 (en) | 2013-10-24 |
ES2452965T3 (es) | 2014-04-03 |
KR101225233B1 (ko) | 2013-01-22 |
KR20120120453A (ko) | 2012-11-01 |
ZA201002356B (en) | 2010-12-29 |
TWI371277B (en) | 2012-09-01 |
RU2010108162A (ru) | 2011-09-10 |
WO2009031011A2 (en) | 2009-03-12 |
AU2008294473A1 (en) | 2009-03-12 |
EP2215087A2 (en) | 2010-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR068369A1 (es) | Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina" | |
ECSP088904A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
CL2010001348A1 (es) | Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad. | |
GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
HN2009000784A (es) | Dihidropirazolonas sustituidas | |
CL2011000835A1 (es) | Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras. | |
CL2008003593A1 (es) | Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer | |
SV2009002858A (es) | Nueva forma polimorfica y la forma amorfa de 5- cloro-n-([(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il]-metil)-2-tiofenocarboxamida | |
NI201000055A (es) | 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa. | |
CL2008002295A1 (es) | Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
CL2008002162A1 (es) | Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras. | |
CL2009000004A1 (es) | Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia. | |
CR11684A (es) | Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa | |
CR20110100A (es) | Nuevos derivados de sulfamida sustituida | |
GT201000047A (es) | Mejoras en compuestos organicos o relacionadas con los mismos | |
ECSP088925A (es) | Nitrilos espirocíclicos como inhibidores de proteasa | |
UY31133A1 (es) | "oxazolidinonas sustituidas y su uso" | |
CL2008001990A1 (es) | Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer. | |
UY29417A1 (es) | Agentes endoparasiticidas | |
CL2009001089A1 (es) | Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
CL2009000665A1 (es) | Compuestos derivados de pirrolidinilo; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la ansiedad, depresion o ambas. | |
CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. | |
CR11869A (es) | 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |